The Journal of Neuroscience

<https://jneurosci.msubmit.net>

JN-RM-2592-20R2

GPER in the rostral ventromedial medulla is essential for mobilizing descending inhibition of itch

Weifang Rong, Shanghai Jiaotong University School of Medicine
Ting Gao, Shanghai Jiaotong University School of Medicine
Li Dong, Shanghai Jiaotong University School of Medicine
Jiahong Qian, Shanghai Jiaotong University School of Medicine
Xiaowei Ding, Shanghai Jiaotong University School of Medicine
Yi Zheng, Shanghai Jiaotong University School of Medicine
Meimei Wu, Shanghai Jiaotong University School of Medicine
Li Meng, Shanghai Jiaotong University School of Medicine
Yingfu Jiao, Shanghai Jiaotong University School of Medicine
Po Gao, Shanghai Jiaotong University School of Medicine
Ping Luo, Shanghai Jiaotong University School of Medicine
Guohua Zhang, Shanghai Jiaotong University School of Medicine
Changhao Wu, University of Surrey
Xueyin Shi, Shanghai Jiaotong University School of Medicine

Commercial Interest:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

**GPER in the rostral ventromedial medulla is essential for mobilizing
descending inhibition of itch**

Ting Gao^{1,2#}, Li Dong^{1,2#}, Jiahong Qian^{2,3#}, Xiaowei Ding^{1,2}, Yi Zheng², Meimei Wu^{1,2},
Li Meng², Yingfu Jiao^{2,3}, Po Gao^{2,3}, Ping Luo², Guohua Zhang², Changhao Wu⁴,
Xueyin Shi^{1*} and Weifang Rong^{1,2*}

¹Department of Anesthesiology, Xinhua Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai 200127, China

²Department of Anatomy and Physiology, Shanghai Jiao Tong University School of
Medicine, Shanghai 200025, China

³Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai 200127, China

⁴School of Biosciences and Medicine, University of Surrey, Guildford, UK

[#]Authors contribute equally to the work

^{*}Correspondence: weifangrong@shsmu.edu.cn ;shixueyin1128@163.com

Abbreviated title: GPER mobilizes inhibition of itch.

Number of pages: 46

Number of figures: 11

Word count: Abstract: 184 (250 words maximum, including citations)

Significance statement: 120 (120 words maximum)

Introduction: 650 (650 words maximum, including citations)

Discussion: 1394 (1500 words maximum, including citations)

Conflict of interest: The authors declare no competing interests.

Acknowledgments: Authors wish to acknowledge financial support from The National Natural Science Foundation of China (grant #81570493 & 81873728), The Science and Technology Commission of Shanghai Municipality (grant #18JC1420302) and Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (grant #JZPI201705). CW acknowledges the support from Biotechnology and Biological Sciences Research Council (BB/P004695/1) and National Institute of Aging (1R01AG049321-01A1).

Abstract

Chronic itch is a troublesome condition and often difficult to cure. Emerging evidence suggests that the periaqueductal gray-rostral ventromedial medulla (PAG-RVM) pathway may play an important role in regulation of itch, but the cellular organization and molecular mechanisms remain incompletely understood. Here, we report that a group of RVM neurons distinctively express the G protein-coupled estrogen receptor (GPER), which mediates descending inhibition of itch. We found that GPER⁺ neurons in RVM were activated in chronic itch conditions in rats and mice. Selective ablation or chemogenetic suppression of RVM GPER⁺ neurons resulted in mechanical allodynia and increased scratching in response to pruritogens, whereas chemogenetic activation of GPER⁺ neurons abrogated itch responses, indicating that GPER⁺ neurons are antipruritic. Moreover, GPER-deficient mice and rats of either sex exhibited hypersensitivity to mechanical and chemical itch, a phenotype reversible by μ type opioid receptor (MOR) antagonism. Additionally, significant MOR phosphorylation in the RVM was detected in chronic itch models in wild-type but not in GPER^{-/-} rats. Therefore, GPER not only identifies a population of medullary antipruritic neurons but may also determine the descending antipruritic tone through regulating μ -opioid signaling.

Significance Statement (120 words maximum)

Therapeutic options for itch are limited due to as yet incomplete understanding of the mechanisms of itch processing. Our data have provided novel insights into the cellular organization and molecular mechanisms of descending regulation of itch in normal and pathological conditions: GPER⁺ neurons (largely GABAergic) in the RVM are anti-pruritic neurons under tonic opioidergic inhibition; activation of GPER promotes phosphorylation of MOR and dis-inhibition of the anti-pruritic GPER⁺ neurons from inhibitory opioidergic inputs; failure to mobilize GPER⁺ neurons may result in exacerbation of itch. Our data also illuminate on some of the outstanding questions in the field, such as the mechanisms underlying sex bias in itch, pain and opioid analgesia and the paradoxical effects of morphine on pain and itch.

Introduction

The periaqueductal gray (PAG)-rostral ventromedial medulla (RVM) system plays a well-established role in descending modulation of pain transmission in the spinal cord (Chen and Heinricher, 2019; Denk et al., 2014; Kim et al., 2018; Liu et al., 2018). RVM, consisting of the midline nucleus raphe magnus (NRM) and the adjacent reticular structures, receives extensive projections from PAG and in turn exerts bi-directional (inhibition or facilitation) influences on spinal cord pain transmission. These effects have been attributed to the activity of electrophysiologically-identified ON and OFF neurons, which are presumed to mediate facilitation and inhibition of pain, respectively (Fields et al., 1983; Fields et al., 1991; Mason et al., 1992). In addition, the PAG-RVM system may also be crucial for itch regulation. Activation of Tac1⁺ neurons in ventrolateral PAG was found to induce spontaneous scratching in mice. Notably, this effect was relayed by RVM neurons, whose identity remains to be determined (Gao et al., 2019).

Serotonergic neurons constitute approximately one fourth of the total neuronal population in RVM (Gu and Wessendorf, 2007). Accumulating evidence indicates that RVM serotonergic neurons may play a role facilitating itch. Accordingly, mice lacking 5-HT neurons in the RVM showed attenuated pruritic behavior evoked by compound 48/80 (Liu et al., 2014). Pharmacological ablation of bulbospinal serotonergic (5-HT) fibers also significantly reduced the number of scratching elicited by chloroquine. Furthermore, the bulbospinal serotonergic fibers facilitate itch by augmenting

GRP-GRPR signaling via 5-HT_{1A} receptor (Zhao et al., 2014). Until recently, however, little is known about the role of the non-serotonergic neurons in RVM in itch regulation. Electrophysiologically-identified ON and OFF neurons, largely non-serotonergic neurons (Mason, 1997; Potrebic et al., 1994), exhibit opposing activity in response to intradermally-applied pruritogens (Follansbee et al., 2018), suggesting that they may play differential roles in regulation of itch in addition to regulation of pain. It is possible that in addition to the itch-facilitating serotonergic neurons there may be a different population of anti-pruritus neurons in RVM. Identification of this new population of anti-pruritus neurons in RVM will be a major step forward in understanding the mechanisms of itch.

Opioid signaling is predominant within the PAG-RVM system. Indeed, PAG-RVM is enriched with the μ type opioid receptor (MOR), activation of which results in powerful analgesia (Eippert et al., 2009; Harasawa et al., 2016; Meng et al., 1998). However, itch is one of the most common side effects of μ opioids. The mechanisms underlying the differential effects of MOR activation on pain and itch remain to be determined. Nevertheless, there has been indirect evidence suggesting that MOR located at supraspinal structures such as the RVM may mediate opioid-induced itch both in rodents and in primates (Ko et al., 2004; Ding et al., 2015; Moser and Giesler, 2014).

Previous reports indicate that the PAG-RVM system is sexually dimorphic and

morphine preferentially activates the PAG-RVM pathway in rats (Loyd et al., 2007; Loyd and Murphy, 2006). This raises the possibility that estrogen might inhibit opioid signaling in PAG-RVM system, thereby contributing to the well-documented gender differences in pain, itch and opioid analgesia (Abraham et al., 2018; Green et al., 2006; Mogil, 2012; Sanoja and Cervero, 2010; Stumpf et al., 2013; Verzillo et al., 2014). This possibility is quite likely since 17β -estradiol (E2) may rapidly uncouple MOR from activating the G protein-regulated inwardly rectifying potassium channel (GIRK) (Lagrange et al., 1997) and that μ opioid analgesia is primarily mediated through activation of GIRK (Blanchet and Luscher, 2002). E2 acts by activating nuclear receptors $Er\alpha$ ($Er\beta$) or the G protein coupled estrogen receptor, GPER. We have recently demonstrated that in human neuroblastoma SH-SY5Y cells, activation of GPER promotes MOR phosphorylation in a calcium-PKC dependent manner (Ding et al., 2019). Furthermore, in pilot experiments we found that RVM is enriched with GPER and MOR. These data have led us to postulate that GPER-mediated inhibition of MOR signaling may play certain roles in descending control of itch, which has been tested in this investigation.

Materials and Methods

Animals. Gper-Cre mice (female, 10 weeks old), GPER^{-/-} mice (male and female, 8-10 weeks old), GPER^{-/-} rats (male and female, 10-12 weeks old) and their age and gender-matched WT controls were used for experiments. Gper-Cre mice were generated in Model Organisms Inc (Shanghai) by knocking the 2A-Cre gene fragment into the Gper gene stop codon based on CRISPR/Cas9 system and has been validated through GPER RNAscope *in situ* hybridization (Zheng et al., 2020). GPER^{-/-} rats and mice were both constructed in BIORAY laboratories Inc (Shanghai). GPER^{-/-} rats (Luo, et al, 2017) were generated through the CRISPR/Cas9 gene-editing approach with a 139-bp deletion of the Gper gene (Gene ID:171104). GPER^{-/-} mice were also generated by using the CRISPR/Cas9 system with a 17-bp deletion of the Gper gene (Gene ID: 76854). WT rats and mice were provided by The Animal Facility of Shanghai Jiao Tong University School of Medicine. All animals were housed on a 12-h light/dark cycle with access to food and water *ad libitum*. All experiments were conducted in compliance with the governmental regulations on the use of experimental animals and were approved by the Ethic Committees of Shanghai Jiao Tong University School of Medicine.

Drug preparation. Serotonin hydrochloride (5-HT, Cat#H9523), chloroquine (Cat#C6628), histamine (Cat#H7125), compound 48/80 (Cat#C2313), diphenylcyclopropenone (DCP, Cat#177377) were purchased from Sigma-Aldrich (St. Louis, MO). DCP was dissolved in acetone and other reagents were dissolved in

sterile saline. Clozapine-N-oxide (CNO, Cat#C0832), the exogenous DREADD ligand, was also from Sigma-Aldrich and dissolved in saline with gentle vortex for mixing. Imiquimod cream was from Aldara and naltrexone HCL (Cat#S2103) was purchased from Selleck Chemicals. G15 (Cayman chemical, Cat#14673) was dissolved in DMSO as stock and diluted in saline before use. All viruses used in the experiment were provided by Shanghai Taitool Bioscience Co. Ltd.

Acute chemical itch. Mice or rats were shaved on the back neck and handled daily for 5 days before the behavioral tests. During the test, animals were allowed to acclimate to the environment for 20-30 min firstly and then were removed from the chamber and intradermally injected with different pruritic compounds, histamine (500 µg/20 µL), chloroquine (150 µg/20 µL) or compound 48/80 (50 µg/20 µL) for mice. Higher doses of histamine (600 µg) or chloroquine (200 µg) were given to the mice in order to observe if chemogenetic activation of GPER⁺ neurons would attenuate acute chemical itch. For rats, the doses of the chemicals were: histamine (2.5 mg/50 µL), 5-HT (200 µg/50 µL), chloroquine (2.5 mg/50 µL). Immediately after the injection, animals were placed individually in the observation boxes and videotaped for 30 min. The scratching bouts with the hind-paw directed to injection sites were counted by an investigator who was blinded to the genotypes and treatments.

Chronic itch models. For diphenylcyclopropanone (DCP)-induced contact dermatitis mouse model, animals were shaved on the back neck 3 days before sensitization and

180 were handled daily. Mice were sensitized with 0.2 mL DCP (1% dissolved in acetone)
181 by painting on the shaved back neck. Seven days after the sensitization, the back neck
182 was painted with 0.2 mL of 0.5% DCP on day 1, 4, 5, 6, 7, 10, 11 and 14 (Liu et al.,
183 2016). The animals were placed individually in the observation box after painting
184 each day and videotaped for 1 hr. Spontaneous scratching behaviors were recorded on
185 day 15 for 1 hr. As with the mouse experiment, rats were sensitized with 0.5 mL of
186 DCP (4% dissolved in acetone). Seven days after the sensitization the back neck was
187 painted with 0.5 mL of 2% DCP for 7 consecutive days. Scratching bouts were
188 counted for 1 hr each day after painting. Spontaneous scratching behaviors were
189 recorded on day 8 for 1 hr. For imiquimod-induced psoriasis model, the back neck
190 was also shaved and received topical application of 12.5 mg imiquimod daily for 7
191 consecutive days (mice for 6 days with 6 mg imiquimod). Spontaneous scratch bouts
192 were recorded before painting the back neck with imiquimod cream on every testing
193 day. The investigator who counted the itch behavior was blinded to the genotypes and
194 treatments.

195
196 **Acute mechanical itch (alloknesis).** To test acute mechanical itch, mice or rats were
197 shaved on the back neck and allowed to acclimate to the environment for 20 min daily
198 for 3 consecutive days before the experiment. On the testing day, the back neck was
199 probed with light von Frey filaments (Aesthesio). Each stimulus was applied 1s and
200 repeated 5 times at 5 s intervals. Hind paw scratching toward the poked site was
201 considered as a positive response. The experimenter was blinded to the genotypes.

202

203 **Tail-flick test.** Mice were habituated to the testing room and handled before test. On
204 the testing day, mice were gently restrained in experimenter's hand with a cotton glove.
205 The protruding one-third of the tail was then immersed into a water bath (52 °C), the
206 latency of tail flick response was measured, with a cut off time of 10 s to avoid tissue
207 damage. The experimenter was blinded to the genotypes in this experiment.

208

209 **Haematoxylin and eosin (HE) staining.** Rats or mice were perfused with normal
210 saline followed by 4% paraformaldehyde after an overdose of sodium pentobarbital.
211 The skin of the back neck was removed and post-fixed in 4% PFA. The tissue was
212 embedded in paraffin and then consecutively sectioned into 15 µm slices. The tissue
213 slices were then stained with commercial reagents for HE according to the
214 instructions in the manual. Tissue histology was observed under a microscope (Leica
215 DM2500, Leica Microsystems Limited), photographed and analyzed by an
216 investigator who was blinded to the genotypes and treatments. For DCP-induced
217 contact dermatitis models, the skin lesion severity was evaluated using 4-point scoring
218 system (Mann et al., 2012). Briefly, 0 denotes normal skin histology and 1-4 denote
219 increasing severity of tissue damage and inflammation: 1, the epidermis is slightly
220 thickened with slight inflammatory infiltration; 2, thickening of epidermis is easily
221 identified with moderate inflammatory cell infiltration but minimal epidermal damage;
222 3, there exist moderate epidermal damage and more inflammatory cell infiltration; 4,
223 over 50% of the epidermal layer is damaged with intense inflammatory cells

infiltration. For the IMQ-induced psoriasis models, the skin pathology was evaluated according to Psoriasis Area Severity Index (PASI) scoring system (Fredriksson and Pettersson, 1978). Erythema, infiltration and desquamation were scored separately on a scale from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; and 4, very marked. The total score indicates severity of skin pathology.

Immunofluorescence. Rats or mice were euthanized with an overdose of sodium pentobarbital and were then perfused with saline followed by 4% paraformaldehyde. Brainstem was removed and post-fixed in 4% PFA at 4°C overnight, followed by cryoprotection in 30% sucrose. The tissue of interest was cut into 25 µm slices. The slices were blocked with 50 mM PBS containing 10% normal goat or donkey serum and 1% TritonX-100 at room temperature for 2 hr, followed by incubation with primary antibodies at 4 °C overnight and secondary antibodies at room temperature for 2 hr. Primary antibodies used in these experiments were rabbit anti-GPER (1:500, Lifespan, LS-A4272), mouse anti-c-Fos (1:500, Abcam, ab208942), rabbit anti-c-Fos (1:1000, Cell Signaling Technology, 2250S), mouse anti-GAD67 (1:500, Millipore, MAB5406), goat anti-5-HT (1:1000, Neuromics, GT-20079), guinea pig anti-MOR (1:500, Neuromics, GP10106) and mouse anti-Leu enkephalin antibody (1:100, Abcam, ab150346). The secondary antibodies included donkey anti-goat 568 (1:1000, Invitrogen, A11057), donkey anti-rabbit 488 (1:1000, Invitrogen, A21206), goat anti-rabbit 488 (1:1000, Invitrogen, A11034), goat anti-mouse 568 (1:1000, Invitrogen, A11031) and goat anti-guinea pig 568 (1:1000, Invitrogen, A11075). The nuclei were

stained with DAPI (1:1000, Thermo Fisher Scientific, PA5-62248). Images were visualized under the fluorescent microscope (Leica DM2500, Leica Microsystems Limited). Specificity of the primary antibodies for c-Fos, GAD67 and MOR immunofluorescence has been validated in numerous previous studies (An et al., 2020; Wei et al., 2015; Nassirpour et al., 2010). Amongst several commercial primary antibodies for GPER we have tested, LS-A4272 was chosen for GPER immunofluorescence since it seemed to produce least nonspecific staining. Furthermore, we found that the distribution of GPER immunofluorescence in various tissues using LS-A4272 was consistent with GPER mRNA expression (Zheng, et al, 2020).

Western blot. Total protein from freshly dissected RVM was isolated and protein concentration was determined using BCA assay (Pierce, Rackford, IL). 25 µg of total proteins was electrophoresed on a 10% SDS-PAGE gel and transferred onto a PVDF membrane, and then blocked with 5% non-fat dried milk or 5% BSA. Subsequently, the membranes were incubated with different primary antibodies for 24 h at 4°C: rabbit anti-GPER (1:1000, Abcam, ab39742), rabbit anti-pMOR (1:1000, Cell Signaling Technology, 3451), rabbit anti-MOR (1:500, Novus, NBP1-31180) and mouse anti-β-actin (1:3000, Bioworld Technology, BS6007M), followed by peroxidase-conjugated secondary antibodies: anti-rabbit (1:3000, Bio-Rad, 170-6515) or anti-mouse (1:3000, Bio-Rad, 170-6516.). Immunoreactive bands were visualized using chemi-luminescence reagent (Thermo, Indianapolis, IN). Peptide pre-absorption

test was conducted to identify the specific band for GPER. The immunoreactive bands for MOR and pMOR were determined by their predicted molecular weight and according to the manufacturer's datasheets. The density of specific bands was analyzed using NIH ImageJ software and was normalized against the loading controls (β -actin).

TUNEL staining. Apoptotic GPER⁺ neurons were analyzed using a terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end labeling (TUNEL) assay kit (In Situ Cell Death Detection Fluorescein, Roche, Germany). Briefly, after fixation in 4% PFA for 15 min, brain slices were rinsed with PBS three times and permeabilized with 0.1% Triton-X100 in PBS for 2 min. Then the slices were stained using TUNEL staining kit and subsequently counterstained with DAPI for 10 min. Images were taken using a fluorescent microscope (Leica DM2500, Leica Microsystems Limited).

Microinjection of virus into the RVM. We injected adeno-associated viruses (AAV) to manipulate RVM neurons of 10 weeks old mice, and the behavior tests were performed 4-5 weeks after viral injection. In brief, mice were anesthetized with 60 mg/kg pentobarbital sodium and secured in a stereotactic frame (RWD Instruments, Shenzhen, China). The skull was exposed by midline scalp incision and a hole was drilled on the skull to allow passage of glass pipette filled with the virus. Viral injections were performed using the following coordinates: -5.88 mm from bregma, 0

mm from midline and 5.7 mm ventral to skull. The following virus were used in this study: AAV-hSyn-hM4D(Gi)-mCherry virus (AAV2/9, 3.3×10^{12} v.g./mL), AAV-hSyn-DIO-hM4D(Gi)-mCherry virus (AAV2/9, 1.82×10^{13} v.g./mL), AAV-hSyn-DIO-hM3D(Gq)-eGFP virus (AAV2/9, 1.61×10^{13} v.g./mL), or AAV-CAG-DIO-taCasp3-TEVp virus (AAV2/9, 3.7×10^{12} v.g./mL). Injection volume was 400 nL. The pipette was left in place for about 10 min after the injection, and the animals were allowed to recover under a heating lamp before returning to their home cage. The animals with incorrect injection sites were excluded for further analysis in all experiments.

PCR. For genotype identification of Gper-Cre mice, total DNA was extracted from mouse tail and then performed with RT-PCR, the products were analyzed with agarose gel electrophoresis. The primers (5' to 3') used are as follows: P1 (forward: CAGCTTCCTGGGAGAGACCTTCAG); P2 (reverse: ACATGGTGCTCCCATAGCATGGCC) and P3 (forward: AGAGTTCTCCATCAGGGATCTGAC). For verification of GPER^{-/-} mice: total DNA was extracted from mouse tail and performed with RT-PCR. DNA sequencing was used to analyze the products. The primers (5' to 3') used are as follows: ACTAACAGGCTCCCAGGACGAT (forward) and CATCCAGGTGAGGAAGAAGACG (reverse). For verification of GPER^{-/-} rats, total RNA was extracted from RVM with Trizol (Invitrogen, Shanghai, China) following the manufacturer's instructions. For reverse transcription, 500 ng of total RNA was used to synthesize cDNA by using ThermoScript RT-PCR System kit (Invitrogen).

Real-time reverse-transcription PCR or RT-PCR followed by agarose gel electrophoresis was used to analyze the gene expression level. The relative level of Gper mRNA was calculated by the method of $2^{-\Delta\Delta C_t}$, and GAPDH was used as the loading control. The primer pairs (5' to 3') are listed as follows:

GAPDH: GTGATCGCTCTCTTCCTCTC (forward) and
GTCTGGGATAGTCATCTTCTC (reverse);

Primer 1 (GPER) CTGAACATCAGCAATATGTG (forward) and
CTGATGTTACCCACCAAGATG (reverse); cover the deletion fragment;

Primer 2 (GPER) CATCCTCATCTTGGTGGTGAAC (forward) and
CACCTCGATCAGGGAGTCGG (reverse); cover the deletion fragment;

Primer 3 (GPER) CATCCTCATCTTGGTGGTGAAC (forward) and
CACCTCGATCAGGGAGTCGG (reverse); cover the deletion fragment;

Control primer CGCTCAAGGCAGTCATACCA (forward) and
CCCCTGTCCGTTTTCCTCTA (reverse); cover the control fragment.

Statistics. Statistics were performed with GraphPad Prism v.8.0, and data are presented as mean $\pm$ s.e.m. All statistical analysis was two-tailed. Paired or unpaired Student's *t*-tests was used to compare two groups. For multiple comparisons, one-way ANOVA or two-way ANOVA was used, followed by the Tukey or Bonferroni post-tests. A *p* value of less than 0.05 is considered as indicating statistical significance. Asterisks in figures denote *p* values as follows: **p* < 0.05, ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001.

Results

RVM is engaged in chronic itch conditions and non-selective inhibition of RVM neurons increases mechanical allodynia

The cellular organization of RVM in itch processing and the importance in pathological itch is still poorly understood, despite evidence suggesting RVM serotonergic neurons may have a role facilitating itch. We asked whether the RVM would be engaged in chronic itch conditions and how non-selective inhibition of RVM neurons would impact on itch sensation. To address these questions, we firstly examined the expression of c-Fos (a neuronal activity marker) in the RVM under chronic itch conditions. We found that the number of c-Fos⁺ neurons in the RVM were increased significantly in the diphenylcyclopropenone (DCP)-induced chronic contact dermatitis (Sun et al., 2009) mouse and rat models (Fig. 1A-E). Next, we utilized a chemogenetic approach of designer receptors exclusively activated by designer drugs (DREADDs) (Armbruster et al., 2007) to non-selectively inhibit resident RVM neurons. Adeno-associated virus (AAV) carrying the inhibitory DREADD receptor hM4Di fused with mCherry were injected into the RVM of wild-type (WT) mice (Fig. 1F, G) and mechanical itch was tested 30 min following administration of hM4Di agonist clozapine-N-oxide (CNO) or saline 4 weeks after virus injection. Interestingly, we found that activation of hM4Di, thus nonselective inhibition of RVM neurons, led

to significant increases in allodynia scores induced by light mechanical stimulations (Fig. 1H). In contrast, tail flick latency in response to noxious heat stimulation was significantly increased following activation of hM4Di (Fig. 1I). CNO was without significant effect on allodynia in mice pre-injected with the control virus (AAV-hSyn-mCherry, Fig. 1J). These results indicate that RVM is engaged in chronic itch conditions and non-selective inhibition of RVM neurons has a net facilitatory effect on itch sensation, implying that there may indeed exist anti-pruritic neurons in RVM in addition to the pro-pruritic serotonergic neurons.

Selective ablation of RVM GPER⁺ neurons aggravates acute and chronic itch

In pilot experiments GPER was found to be enriched in rat RVM (Fig. 2A, B). Double immunofluorescent staining indicated that GPER⁺ neurons were non-serotonergic but largely GABAergic (Fig. 2C-E). In 6 sections from 3 rats, 147 GPER⁺ neurons and 226 5-HT⁺ neurons were counted, and none of these neurons showed co-labeling. However, 74.8% of GPER⁺ neurons were also strongly immunoreactive to GAD67, a selective marker for GABAergic neurons, although GAD67⁺ neurons were much more numerous than GPER⁺ neurons in this region. To test whether GPER⁺ neurons in the RVM were involved in itch modulation, we conducted c-Fos immunofluorescence to detect the activation of these neurons in itch conditions. We found that GPER⁺ neurons were significantly activated in DCP-induced chronic contact dermatitis in both rat and mouse models (Fig. 2F, G). It was estimated that 55.23% and 39.51% of GPER⁺ neurons were activated (c-Fos⁺) in the rat and mouse chronic contact

dermatitis models, respectively. Furthermore, 54.77% and 71.71% of c-Fos⁺ neurons were GPER⁺ in the rat and mouse models, respectively, suggesting engagement of GPER⁺ neurons in chronic itch conditions.

Then we asked whether ablation of RVM GPER⁺ neurons would be sufficient to alter itch-related behavior. To address this question, Cre-dependent AAV-CAG-DIO-taCasp3-TEVp (Yang et al., 2013) was injected into the RVM of Gper-Cre mice (with WT mice as control) to selectively ablate the GPER⁺ neurons (Fig. 3A).

Western blot analysis conducted on day 35 following the viral infection showed a significant reduction of GPER protein level in the RVM of Gper-Cre mice injected with AAV-CAG-DIO-taCasp3-TEVp (Fig. 3B, C). Moreover, TUNEL staining further confirmed increased apoptosis of RVM neurons in the infected Gper-cre mice (Fig. 3D, E). We found that the number of hind-paw scratching in response to light mechanical stimulations (0.08 g and 0.3 g) was increased significantly in Gper-Cre mice injected with AAV-CAG-DIO-taCasp3-TEVp compared with the WT mice injected with the same virus (Fig. 3F). Acute chemical itch behaviors in response to intradermal chloroquine (CQ) and histamine were also increased in the Gper-Cre mice injected with the virus than in the WT mice (Fig. 3G, H). In a separate cohort of WT and Gper-Cre mice injected with the virus, we constructed a chronic contact dermatitis model by using DCP. Mice with selective ablation of GPER⁺ neurons

showed more robust scratch bouts on every testing day compared with the WT mice (Fig. 3I-K). These results suggest that RVM GPER⁺ neurons likely play an antipruritic role, in contrast to the RVM serotonergic neurons which have been shown to facilitate itch (Zhao et al., 2014).

Chemogenetic inhibition or activation of RVM GPER⁺ neurons differentially modulates itch-related behaviors

Considering that ablation of GPER⁺ neurons might cause unpredictable disturbance of the neural circuitry, we next studied the effect of transient chemogenetic inhibition or activation of the RVM GPER⁺ neurons on chronic or acute itch.

Gper-Cre mice were injected with AAV-hSyn-DIO-hM4D(Gi)-mCherry into the RVM (Fig. 4A, B). Behavior tests were conducted 4 weeks after the virus injection. As shown in Figure 4C, 30 min after administration of the hM4D(Gi) agonist CNO to inhibit GPER⁺ neurons, the mice responded to light mechanical probing of the back neck by hind-paw scratching significantly more vigorously than mice treated with saline. In the same cohorts of mice, acute chemical itch was tested by intradermal injections of CQ or histamine (with 2 days of rest in between) 30 min after administration of CNO or saline. We found that the scratch bouts evoked by CQ and histamine were both significantly increased following chemogenetic inhibition of RVM GPER⁺ neurons (Fig. 4D, E). In the chronic contact dermatitis model, mice treated with DCP showed increased scratching behavior, and inhibition of RVM

422 GPER⁺ neurons on day 5, 7 and 10 seemed to cause further increases in the number of
423 scratching bouts (Fig. 4F), but the difference did not reach statistical significance.

424

425 We next observed the effects of chemogenetic activation of GPER⁺ neurons on
426 itch-related behaviors. We selectively expressed the excitatory DREADD receptor
427 hM3Dq in the RVM GPER⁺ neurons by microinjecting
428 AAV-hSyn-DIO-hM3D(Gq)-eGFP into the RVM of Gper-Cre mice (Fig. 4G, H).
429 Behavior tests were conducted 4 weeks after the viral infection, 30 min following
430 intraperitoneal administration of CNO or saline. Compared with the saline-treated
431 group, CNO-treated mice tended to show fewer scratching responses to light
432 mechanical probing of the back neck, but the difference did not reach statistical
433 significance, presumably due to the very low rate of scratching responses to light
434 touch in these animals (Fig. 4I). However, CNO-treated mice showed significantly
435 decreased number of scratches induced by intradermal injection of CQ or histamine
436 (Fig. 4J, K). In another cohort of mice injected with
437 AAV-hSyn-DIO-hM3D(Gq)-eGFP, contact dermatitis was induced with repeated
438 application of DCP for 14 days. On day 15, the animals were not painted with DCP,
439 but were injected (i.p.) with CNO (to activate GPER⁺ neurons) or saline (as control)
440 respectively; 30 min thereafter, the number of spontaneous scratches were counted for
441 one hour. The CNO-treated mice had significantly fewer hind-paw scratching bouts
442 than the saline-treated mice (Fig. 4L).

GPER deficiency results in hypersensitivity to itch in mice and rats

We next asked the importance of GPER signaling in regulation of itch. Western blot analysis showed that GPER protein expression in the RVM was significantly elevated in the DCP-induced contact dermatitis model in WT rats (Fig. 5A). This pilot data suggests that GPER signaling may be important in itch regulation. To further investigate the role of GPER signaling in acute and chronic itch, we utilized the GPER-knockout (GP^{-/-}) rats (Luo, et al, 2017; Zheng et al., 2020) and mice. It is worth mentioning here that during daily handling or the acclimatization period before behavior tests, spontaneous scratches were similarly rare in GP^{-/-} rats and mice as in their WT counterparts (Fig. 5B).

As shown in Fig. 5C, GPER deficient rats showed remarkable hypersensitivity to light mechanical probing of the back neck by hind-paw scratching compared with the WT rats. The number of scratches evoked by CQ, histamine and 5-HT were also significantly increased in GP^{-/-} rats than in WT rats (Fig. 5D-F). In the DCP-induced chronic contact dermatitis model, GP^{-/-} rats showed significantly more robust scratching within 1 hr after application of DCP than their WT counterparts on every testing day (Fig. 5G). Scratching bouts examined on day 8 (without application DCP) were also markedly increased in the GP^{-/-} rats compared with the WT rats (Fig. 5H). The increased scratching behavior in the GP^{-/-} rats was accompanied by more severe skin lesions than the WT rats, likely due to more intense scratching (Fig. 5I-K). Similar results were obtained in the imiquimod-induced

psoriasis model (Fig. 6). Thus, scratching bouts before or immediately after painting with imiquimod on all the testing days were all increased (Fig. 6B, C), accompanied by increased epidermis thickness in the GPER^{-/-} rats compared with the WT rats (Fig. 6D-F). We have shown above that GPER⁺ neurons, likely having an antipruritic role, were significantly activated in a rat model of chronic itch (Fig. 2F). Interestingly, in the DCP-induced contact dermatitis model, GPER^{-/-} rats showed significantly fewer c-Fos⁺ neurons than WT rats in the RVM (Fig. 7), indicating that GPER may be indispensable for the mobilization of descending inhibition of itch.

Similarly to the observations in GPER^{-/-} rats, we found that GPER^{-/-} mice exhibited hypersensitivity to chemical and mechanical itch (Fig. 8A, C) and increased scratching in the imiquimod-induced psoriasis model (Fig. 8D-G). In WT mice, blockade of GPER by systemic administration of G15 (0.5 mg/kg, i.p.), a GPER antagonist (Dennis et al., 2009), resulted in significant increases in scratching bouts following intradermal injection of the pruritogen compound 48/80 (Fig. 8B). Importantly, although the data presented as far were obtained from female animals, parallel studies were also conducted in male animals. We found that male GPER^{-/-} mice and rats also exhibited mechanical allodynia, hypersensitivity to chemical pruritogens and greatly increased scratching bouts in the chronic itch models (Fig. 8H-J, 9A-E). Thus, these effects are species and sex independent.

GPER modulates itch through regulating μ -opioid signaling

We then set to test the hypothesis that GPER may signal through desensitizing MOR (Ding et al., 2019) in RVM to regulate itch sensation. By immunofluorescence, we found that virtually all GPER⁺ neurons within the rat RVM were strongly immunoreactive for MOR, although MOR⁺ neurons were much more numerous than GPER⁺ neurons (~20% MOR⁺ neurons were GPER⁺) (Fig. 10A). Furthermore, double IHC showed there were enkephalinergic terminals in proximity to GPER⁺ neurons (Fig. 10B). Western blot analysis of the RVM protein lysates showed that MOR expression was significantly decreased whilst phosphorylated MOR (pMOR) expression was markedly increased in WT rats with chronic contact dermatitis compared with the WT control rats. Strikingly, in the chronic contact dermatitis model, GPER^{-/-} rats did not show significant MOR phosphorylation in RVM (Fig. 10C- F). These results indicate that chronic itch may trigger decreased μ opioid signaling in RVM and GPER is required in this process. In other words, the itch phenotype of GPER^{-/-} mice and rats may be due to enhanced MOR signaling. Consistent with this observation, we found that the mechanical allodynia, the hypersensitivity to histamine and the increased chronic itch in DCP-induced contact dermatitis seen in GPER^{-/-} rats or mice were all reversed by the μ opioid antagonist naltrexone (Fig. 11A-D). However, scratching responses to light mechanical stimulations in the WT mice were not affected by naltrexone treatment (Fig. 11E, F).

Discussion

Itch processing in the brain is immensely complex. Recent evidence suggests that the PAG-RVM system, originally known for its bidirectional roles in descending modulation of pain, may also be important in regulation of itch (Follansbee et al., 2018; Gao et al., 2019; Zhao et al., 2014). The current study has provided evidence that GPER-expressing neurons (largely GABAergic) in the RVM are anti-pruritic neurons. These neurons are mobilized in chronic itch conditions likely through GPER-dependent desensitization of μ opioid signaling. The findings provide a new concept in itch regulation that there is a counter mechanism to balance the excitatory action by serotonergic neurons in the PAG-RVM system and that GPER is essential for mobilizing descending inhibition of itch.

RVM GPER⁺ neurons play essential roles in descending inhibition of itch

We found that c-Fos expression was increased in the RVM in the DCP-induced chronic contact dermatitis model in both rats and mice, suggesting that RVM is engaged in chronic itch conditions. Whether itch signal *per se* or scratch-induced pain/tissue damage resulted in activation of RVM neurons is not clear. But the focus here should be that the activated (c-Fos⁺) neurons are deemed to play certain roles in itch regulation, either excitatory or inhibitory. RVM serotonergic neurons facilitate transmission of itch signals in the spinal cord and loss of this facilitatory influence reduces itch (Liu et al., 2014; Zhao et al., 2014). However, we found that non-serotonergic neurons rather than serotonergic neurons were activated in the chronic itch model. We argue that this may imply mobilization of non-serotonergic

anti-pruritic neurons in chronic itch conditions.

Global suppression of RVM neurons by DREADD method was found to result in hypersensitivity to mechanical itch. Hence it seems possible that the antipruritic neurons may be constitutively active and that loss of this anti-pruritic tone may facilitate itch. Understanding the nature of the antipruritic neurons and the molecular mechanisms underlying their tonic activity and mobilization may hold the key to effective management of itch.

Until now, the cellular organization of the RVM in relation to pain or itch control remain poorly understood, due to lack of selective molecular markers for different types of neurons within this region, except for the serotonergic neurons (Chen and Heinricher, 2019; Francois et al., 2017). The current study tends to support GPER as a molecular marker for a population of antipruritic neurons within RVM. This argument is based on three complementary lines of evidence. Firstly, GPER was found to be exclusively confined to non-serotonergic neurons. Secondly, selective ablation of GPER⁺ neurons by Cre-driven overexpression of Caspase3 resulted in mechanical allodynia, hypersensitivity to chemical pruritogens and increased itch-related behaviors in the DCP-induced contact dermatitis model. Thirdly, selective chemogenetic manipulation of the activity of these neurons also led to behavioral changes consistent with GPER⁺ neurons having an anti-pruritic role. In the mechanical allodynia test, light mechanical probing of the back neck mimics normal physiological situations, such as a light breeze over the skin. That this behavior was also altered by chemogenetic manipulations of GPER⁺ neurons indicate that these

neurons may play a role in itch regulation under normal physiological as well as in pathological conditions.

Two functional types of neurons, namely ON and OFF neurons, are presumed to facilitate and inhibit pain transmission in the spinal cord, respectively (Fields et al., 1983; Fields et al., 1991; Mason et al., 1992). But these neurons may not be specific for pain regulation (Mason P, 2005). It has been shown that intradermal pruritogens may cause excitation of a large proportion of electrophysiologically-identified ON neurons and inhibition of a smaller proportion of OFF neurons, suggesting that at least subpopulations of ON and OFF neurons may regulate itch as well as pain (Follansbee et al., 2018). The observation also implies peripheral itch signal may mobilize a subset of ON neurons, presumably to inhibit the itch sensation. The GPER⁺ neurons likely correspond to this subset of ON neurons, since they were mobilized, as evidenced by c-Fos expression, in the chronic contact dermatitis model in both rats and mice. Although the current study has been focused on itch regulation, we do not persist that GPER⁺ neurons specifically inhibit itch. Rather, they might play dual roles in sensory processing, inhibition of itch and facilitation of pain.

We found that GPER⁺ neurons likely are GABAergic neurons since they were mostly immunoreactive to GAD67. RVM GABAergic neurons are heterogeneous in function and in neurochemistry (Pedersen et al., 2011). Interestingly, previous studies suggest that the spinal cord dorsal horn receives substantial GABAergic input from RVM

(Pedersen et al., 2011; Reichling and Basbaum, 1990). Indeed, over half of both ON and OFF cells may be GABAergic (Winkler et al., 2006). Recently, Francois et al demonstrated that activation of RVM GABAergic neurons facilitated mechanical pain by inhibiting dorsal horn enkephalinergic and GABAergic interneurons, whereas Zhang et al showed that dual GABA/enkephalinergic RVM neurons could inhibit behavioral sensitivity to heat and mechanical stimuli (Francois et al., 2017; Zhang et al., 2015). Moreover, in addition to the excitatory serotonergic projections, RVM GABAergic fibers form functional inhibitory synapses with spinal GRPR⁺ neurons, which are critical for the coding of itch sensation in the spinal cord (Liu et al., 2019; Sun and Chen, 2007). These bulbospinal GABAergic neurons were presumed to mediate inhibition of itch (Samineni et al., 2019). Conceivably, GPER⁺ neurons may correspond to this neuronal population.

GPER is required for the mobilization of descending inhibition of itch through desensitizing μ opioid signaling

GPER has been shown to mediate rapid estrogenic effects in a variety of tissues including in the nervous system (Brailoiu et al., 2007; Dun et al., 2009; Paletta et al., 2018; Takanami et al., 2010). We found that GPER expression in RVM was significantly increased in chronic itch conditions. Moreover, GPER deficient rats and mice both exhibited hypersensitive itch phenotype in acute (mechanical and chemical) and chronic itch models. In the DCP-induced contact dermatitis model, GPER^{-/-} rats showed significantly fewer c-Fos⁺ neurons than WT rats in the RVM. These results

indicate that GPER signaling is important in regulation of GPER⁺ neuronal activity and is critical for mobilization of descending inhibition of itch.

Activation of GPER likely promotes activation of GPER⁺ neurons and mobilization of descending inhibition of itch through disinhibition from opioid inputs. Opioid signaling is predominant within the PAG-RVM pathway and activation of the inhibitory μ opioid receptor (MOR) mediates potent analgesia but induces itch (Ko et al., 2004; Miyamoto and Patapoutian, 2011). We detected dense enkephalinergic terminals in proximity to GPER⁺ neurons, suggesting that GPER⁺ neurons, which express MOR, receive direct inhibitory opioidergic inputs. MOR inhibits neuronal activity by interacting with G protein-regulated inwardly rectifying potassium (GIRK) channels (Montandon et al., 2016). Protein kinase-dependent MOR phosphorylation results in desensitization of the receptor (Arttamangkul et al., 2018). Estradiol may rapidly uncouple MOR from activating potassium currents in hypothalamic neurons (Lagrange et al., 1997) and we have found that activation of GPER promotes MOR phosphorylation in SH-SY5Y cells (Ding et al., 2019). Meanwhile, in the current study, we found that MOR phosphorylation was significantly increased in WT but not in GPER^{-/-} rats with chronic contact dermatitis. Furthermore, the hypersensitive itch phenotype of GPER^{-/-} rats and mice was reversed by the μ antagonist naltrexone. These results together suggest that GPER may signal through desensitizing MOR thereby to promote the excitability and mobilization of the antipruritic GPER⁺ neurons.

619
620 Interestingly, we found that male and female GPER-deficient rats and mice exhibited
621 similar hypersensitive itch phenotype. Therefore, GPER signaling in descending
622 control of itch is ubiquitous across species and sex and may be of fundamental
623 biological significance. We reason that the antipruritic GPER⁺ neurons may play
624 critical roles in gating ascending itch signal transmission and they are under tonic
625 inhibitory opioidergic influences mediated by MOR. In normal conditions
626 GPER-mediated MOR phosphorylation may cause some degree of dis-inhibition of
627 GPER⁺ neurons from the opioidergic inputs, thereby to maintain a descending
628 antipruritic tone to prevent animals from being over-responsive to harmless
629 environmental cues. GPER-mediated dis-inhibition is up-regulated in chronic itch
630 conditions, allowing for the mobilization of this critical descending inhibitory
631 pathway.

632
633 In summary, this investigation has provided evidence showing that the GPER⁺
634 neurons in the RVM play a crucial inhibitory role in descending regulation of itch.
635 Activation of GPER promotes phosphorylation of MOR and dis-inhibition of the
636 anti-pruritic GPER⁺ neurons from opioidergic inputs. This mechanism seems essential
637 in the regulation of itch in normal and pathological conditions.

638
639
640 **References**

641 Abraham, A.D., Schattauer, S.S., Reichard, K.L., Cohen, J.H., Fontaine, H.M., Song, A.J., Johnson, S.D.,
642 Land, B.B., and Chavkin, C (2018) Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor
643 Signaling Mediating Analgesia, But Not Aversion. *J Neurosci* 38, 8031-8043.

644 An, J.J., Kinney, C.E., Tan, J.W., Liao, G.Y., Kremer, E.J., and Xu, B.J. (2020). TrkB-expressing
645 paraventricular hypothalamic neurons suppress appetite through multiple neurocircuits. *Nat*
646 *Commun* 11.

647 Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., and Roth, B.L (2007) Evolving the lock to fit the key
648 to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl*
649 *Acad Sci U S A* 104, 5163-5168.

650 Arttamangkul, S., Heinz, D.A., Bunzow, J.R., Song, X., and Williams, J.T (2018) Cellular tolerance at the
651 micro-opioid receptor is phosphorylation dependent. *Elife* 7.

652 Blanchet, C., and Luscher, C (2002) Desensitization of mu-opioid receptor-evoked potassium currents:
653 initiation at the receptor, expression at the effector. *Proc Natl Acad Sci U S A* 99, 4674-4679.

654 Brailoiu, E., Dun, S.L., Brailoiu, G.C., Mizuo, K., Sklar, L.A., Oprea, T.I., Prossnitz, E.R., and Dun, N.J (2007)
655 Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat
656 central nervous system. *J Endocrinol* 193, 311-321.

657 Chen, Q., and Heinricher, M.M (2019) Descending Control Mechanisms and Chronic Pain. *Curr*
658 *Rheumatol Rep* 21, 13.

659 Denk, F., McMahon, S.B., and Tracey, I (2014) Pain vulnerability: a neurobiological perspective. *Nat*
660 *Neurosci* 17, 192-200.

661 Dennis, M.K., Burai, R., Ramesh, C., Petrie, W.K., Alcon, S.N., Nayak, T.K., Bologa, C.G., Leitao, A.,
662 Brailoiu, E., Deliu, E., *et al.* (2009). In vivo effects of a GPR30 antagonist. *Nat Chem Biol* 5,

663 421-427.

664 Ding, H., Hayashida, K., Suto, T., Sukhtankar, D.D., Kimura, M., Mendenhall, V., and Ko, M.C (2015)

665 Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and

666 itch in non-human primates. *Br J Pharmacol* 172, 3302-3312.

667 Ding, X., Gao, T., Gao, P., Meng, Y., Zheng, Y., Dong, L., Luo, P., Zhang, G., Shi, X., and Rong, W (2019)

668 Activation of the G Protein-Coupled Estrogen Receptor Elicits Store Calcium Release and

669 Phosphorylation of the Mu-Opioid Receptors in the Human Neuroblastoma SH-SY5Y Cells. *Front*

670 *Neurosci* 13, 1351.

671 Dun, S.L., Brailoiu, G.C., Gao, X., Brailoiu, E., Arterburn, J.B., Prossnitz, E.R., Oprea, T.I., and Dun, N.J

672 (2009) Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and

673 sensory ganglia. *J Neurosci Res* 87, 1610-1619.

674 Eippert, F., Bingel, U., Schoell, E.D., Yacubian, J., Klinger, R., Lorenz, J., and Buchel, C (2009) Activation

675 of the opioidergic descending pain control system underlies placebo analgesia. *Neuron* 63,

676 533-543.

677 Fields, H.L., Bry, J., Hentall, I., and Zorman, G (1983) The activity of neurons in the rostral medulla of

678 the rat during withdrawal from noxious heat. *J Neurosci* 3, 2545-2552.

679 Fields, H.L., Heinricher, M.M., and Mason, P (1991) Neurotransmitters in nociceptive modulatory

680 circuits. *Annu Rev Neurosci* 14, 219-245.

681 Follansbee, T., Akiyama, T., Fujii, M., Davoodi, A., Nagamine, M., Iodi Carstens, M., and Carstens, E

682 (2018) Effects of pruritogens and algogens on rostral ventromedial medullary ON and OFF cells. *J*

683 *Neurophysiol* 120, 2156-2163.

684 Francois, A., Low, S.A., Sypek, E.I., Christensen, A.J., Sotoudeh, C., Beier, K.T., Ramakrishnan, C., Ritola,

685 K.D., Sharif-Naeini, R., Deisseroth, K. Delp, S. L., Malenka, R. C., Luo, L., Hantman, A. W., Scherrer,
686 G (2017) A Brainstem-Spinal Cord Inhibitory Circuit for Mechanical Pain Modulation by GABA and
687 Enkephalins. *Neuron* 93, 822-839 e826.

688 Fredriksson, T., and Pettersson, U. (1978). Severe psoriasis--oral therapy with a new retinoid.
689 *Dermatologica* 157, 238-244

690 Gao, Z.R., Chen, W.Z., Liu, M.Z., Chen, X.J., Wan, L., Zhang, X.Y., Yuan, L., Lin, J.K., Wang, M., Zhou, L.,
691 Xu, X. H., Sun, Y. G (2019) Tac1-Expressing Neurons in the Periaqueductal Gray Facilitate the
692 Itch-Scratching Cycle via Descending Regulation. *Neuron* 101, 45-59 e49.

693 Green, A.D., Young, K.K., Lehto, S.G., Smith, S.B., and Mogil, J.S (2006) Influence of genotype, dose and
694 sex on pruritogen-induced scratching behavior in the mouse. *Pain* 124, 50-58.

695 Gu, M., and Wessendorf, M (2007) Endomorphin-2-immunoreactive fibers selectively appose
696 serotonergic neuronal somata in the rostral ventral medial medulla. *J Comp Neurol* 502, 701-713.

697 Harasawa, I., Johansen, J.P., Fields, H.L., Porreca, F., and Meng, I.D (2016) Alterations in the rostral
698 ventromedial medulla after the selective ablation of mu-opioid receptor expressing neurons. *Pain*
699 157, 166-173.

700 Kim, J.H., Gangadharan, G., Byun, J., Choi, E.J., Lee, C.J., and Shin, H.S (2018) Yin-and-yang bifurcation
701 of opioidergic circuits for descending analgesia at the midbrain of the mouse. *Proc Natl Acad Sci*
702 U S A 115, 11078-11083.

703 Ko, M.C., Song, M.S., Edwards, T., Lee, H., and Naughton, N.N (2004) The role of central mu opioid
704 receptors in opioid-induced itch in primates. *J Pharmacol Exp Ther* 310, 169-176.

705 Lagrange, A.H., Ronnekleiv, O.K., and Kelly, M.J (1997) Modulation of G protein-coupled receptors by
706 an estrogen receptor that activates protein kinase A. *Mol Pharmacol* 51, 605-612.

707 Liu, C., Liu, T.T., He, Z.G., Shu, B., and Xiang, H.B (2014) Inhibition of itch-related responses by
 708 selectively ablated serotonergic signals at the rostral ventromedial medulla in mice. *Int J Clin Exp*
 709 *Pathol* 7, 8917-8921.

710 Liu, M.Z., Chen, X.J., Liang, T.Y., Li, Q., Wang, M., Zhang, X.Y., Li, Y.Z., Sun, Q., and Sun, Y.G (2019)
 711 Synaptic control of spinal GRPR(+) neurons by local and long-range inhibitory inputs. *Proc Natl*
 712 *Acad Sci U S A*.

713 Liu T., Han Q.J., Chen G., Huang Y., Zhao L.X., Temugin B., Gao Y.G., and Ji R.R (2016) Toll-like receptor 4
 714 contributes to chronic itch, allodynia, and spinal astrocyte activation in male mice. *Pain* 157,
 715 806-817.

716 Liu, Y., Latremoliere, A., Li, X., Zhang, Z., Chen, M., Wang, X., Fang, C., Zhu, J., Alexandre, C., Gao, Z.,
 717 Chen, B., Ding, X., Zhou, J. Y., Zhang, Y., Chen, C., Wang, K. H., Woolf, C. J., He, Z. (2018) Touch and
 718 tactile neuropathic pain sensitivity are set by corticospinal projections. *Nature* 561, 547-550.

719 Loyd, D.R., Morgan, M.M., and Murphy, A.Z (2007) Morphine preferentially activates the
 720 periaqueductal gray-rostral ventromedial medullary pathway in the male rat: a potential
 721 mechanism for sex differences in antinociception. *Neuroscience* 147, 456-468.

722 Loyd, D.R., and Murphy, A.Z (2006) Sex differences in the anatomical and functional organization of
 723 the periaqueductal gray-rostral ventromedial medullary pathway in the rat: a potential circuit
 724 mediating the sexually dimorphic actions of morphine. *J Comp Neurol* 496, 723-738.

725 Luo, P., Wu M.M., Gao P., Gao T., Dong L., Ding X.W., Meng Y.Q., Qian J., Zhang G.H. and Rong W.F
 726 (2017) Stress-related arterial hypertension in Gper-deficient rats. *Sheng Li Xue Bao*. 69, 532-540.

727 Mann, P.C., Vahle, J., Keenan, C.M., Baker, J.F., Bradley, A.E., Goodman, D.G., Harada, T., Herbert, R.,
 728 Kaufmann, W., Kellner, R., Nolte, T., Rittinghausen, S., Tanaka, T. (2012) International

729 harmonization of toxicologic pathology nomenclature: an overview and review of basic principles.

730 Toxicol Pathol 40, 75-135.

731 Mason, P. (1997). Physiological identification of pontomedullary serotonergic neurons in the rat. J

732 Neurophysiol 77, 1087-1098.

733 Mason, P., Back, S.A., and Fields, H.L (1992) A confocal laser microscopic study of

734 enkephalin-immunoreactive appositions onto physiologically identified neurons in the rostral

735 ventromedial medulla. J Neurosci 12, 4023-4036.

736 Mason P (2005) Ventromedial medulla: pain modulation and beyond. J Comp Neurol 493(1):2-8.

737 Meng, I.D., Manning, B.H., Martin, W.J., and Fields, H.L (1998) An analgesia circuit activated by

738 cannabinoids. Nature 395, 381-383.

739 Miyamoto, T., and Patapoutian, A (2011) Why does morphine make you itch? Cell 147, 261-262.

740 Mogil, J.S (2012) Sex differences in pain and pain inhibition: multiple explanations of a controversial

741 phenomenon. Nat Rev Neurosci 13, 859-866.

742 Montandon, G., Ren, J., Victoria, N.C., Liu, H.T., Wickman, K., Greer, J.J., and Horner, R.L (2016)

743 G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by

744 Opioids. Anesthesiology 124, 641-650.

745 Moser, H.R., and Giesler, G.J., Jr (2014) Itch elicited by intradermal injection of serotonin, intracisternal

746 injection of morphine, and their synergistic interactions in rats. Neuroscience 274, 119-127.

747 Nassirpour, R., Bahima, L., Lalive, A.L., Luscher, C., Lujan, R., and Slesinger, P.A. (2010). Morphine- and

748 CaMKII-Dependent Enhancement of GIRK Channel Signaling in Hippocampal Neurons. J Neurosci

749 30, 13419-13430.

750 Paletta, P., Sheppard, P.A.S., Matta, R., Ervin, K.S.J., and Choleris, E (2018) Rapid effects of estrogens on

751 short-term memory: Possible mechanisms. *Horm Behav* 104, 88-99.

752 Pedersen, N.P., Vaughan, C.W., and Christie, M.J (2011) Opioid receptor modulation of GABAergic and

753 serotonergic spinally projecting neurons of the rostral ventromedial medulla in mice. *J*

754 *Neurophysiol* 106, 731-740.

755 Potrebic, S.B., Fields, H.L., and Mason, P. (1994). Serotonin immunoreactivity is contained in one

756 physiological cell class in the rat rostral ventromedial medulla. *J Neurosci* 14, 1655-1665.

757 Reichling, D.B., and Basbaum, A.I (1990) Contribution of brainstem GABAergic circuitry to descending

758 antinociceptive controls: I. GABA-immunoreactive projection neurons in the periaqueductal gray

759 and nucleus raphe magnus. *J Comp Neurol* 302, 370-377.

760 Samineni, V.K., Grajales-Reyes, J.G., Sundaram, S.S., Yoo, J.J., and Gereau, R.W.t (2019) Cell

761 type-specific modulation of sensory and affective components of itch in the periaqueductal gray.

762 *Nat Commun* 10, 4356.

763 Sanoja, R., and Cervero, F (2010) Estrogen-dependent changes in visceral afferent sensitivity. *Auton*

764 *Neurosci* 153, 84-89.

765 Stumpf, A., Burgmer, M., Schneider, G., Heuft, G., Schmelz, M., Phan, N.Q., Stander, S., and Pfleiderer,

766 B (2013) Sex differences in itch perception and modulation by distraction--an fMRI pilot study in

767 healthy volunteers. *PLoS One* 8, e79123.

768 Sun, Y.G., and Chen, Z.F (2007) A gastrin-releasing peptide receptor mediates the itch sensation in the

769 spinal cord. *Nature* 448, 700-703.

770 Sun, Y.G., Zhao, Z.Q., Meng, X.L., Yin, J., Liu, X.Y., and Chen, Z.F (2009) Cellular basis of itch sensation.

771 *Science* 325, 1531-1534.

772 Takanami, K., Sakamoto, H., Matsuda, K., Hosokawa, K., Nishi, M., Prossnitz, E.R., and Kawata, M (2010)

773 Expression of G protein-coupled receptor 30 in the spinal somatosensory system. Brain Res 1310,
774 17-28.

775 Verzillo, V., Madia, P.A., Liu, N.J., Chakrabarti, S., and Gintzler, A.R (2014) Mu-opioid receptor splice
776 variants: sex-dependent regulation by chronic morphine. J Neurochem 130, 790-796.

777 Wei, P.F., Liu, N., Zhang, Z.J., Liu, X.M., Tang, Y.Q., He, X.B., Wu, B.F., Zhou, Z., Liu, Y.H., Li, J., et al.
778 (2015). Processing of visually evoked innate fear by a non-canonical thalamic pathway (vol 6,
779 6756, 2015). Nat Commun 6.

780 Winkler, C.W., Hermes, S.M., Chavkin, C.I., Drake, C.T., Morrison, S.F., and Aicher, S.A (2006) Kappa
781 opioid receptor (KOR) and GAD67 immunoreactivity are found in OFF and NEUTRAL cells in the
782 rostral ventromedial medulla. J Neurophysiol 96, 3465-3473.

783 Yang, C.F., Chiang, M.C., Gray, D.C., Prabhakaran, M., Alvarado, M., Juntti, S.A., Unger, E.K., Wells, J.A.,
784 and Shah, N.M (2013) Sexually dimorphic neurons in the ventromedial hypothalamus govern
785 mating in both sexes and aggression in males. Cell 153, 896-909.

786 Zhao, Z.Q., Liu, X.Y., Jeffry, J., Karunarathne, W.K., Li, J.L., Munanairi, A., Zhou, X.Y., Li, H., Sun, Y.G., Wan,
787 L., Wu, Z. Y., Kim, S., Huo, F. Q., Mo, P., Barry, D. M., Zhang, C. K., Kim, J. Y., Gautam, N., Renner, K.
788 J., Li, Y. Q., Chen, Z. F (2014) Descending control of itch transmission by the serotonergic system
789 via 5-HT1A-facilitated GRP-GRPR signaling. Neuron 84, 821-834.

790 Zheng, Y., Wu M.M., Gao T., Meng L., Ding X.W., Meng Y.Q., Jiao Y.F., Luo P., He Z.Q., Sun T., Zhang G.H.,
791 Shi X.Y., Rong W.F. (2020) GPER deficient rats exhibit lower serum corticosterone level and
792 increased anxiety-like behavior. Neural Plasticity, 2020:8866187.

793

794

Figure legends

Figure 1. RVM is engaged in chronic itch conditions and non-selective inhibition of RVM neurons increases mechanical allodynia.

A-D, Representative IHC images showing the distribution of c-Fos⁺ neurons in the RVM of female control mouse (**A**) and DCP-induced contact dermatitis mouse (**B**), female control rat (**C**) and contact dermatitis rat (**D**). Scale bar=50 μ m. **E**, The number of c-Fos⁺ neurons in the RVM of control and contact dermatitis models. n=6-7 slides from 3 animals for each group; One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. $F=32.84$, *** $p = 0.0002$ for Control mice vs. DCP-treated mice, **** $p<0.0001$ for Control rats vs. DCP-treated rats. **F**, Schematic showing the injection of AAV-hM4Di-mCherry into the RVM of female WT mouse. **G**, A representative image showing the expression of hM4Di-mCherry in the RVM section (4 weeks after virus injection). Scale bar=50 μ m. **H**, Chemogenetic non-selective inhibition of RVM neurons by injecting CNO (0.5 mg/kg, i.p.) increased mechanical allodynia. n=6 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test. $F_{(1,70)}=51.25$, 0.08g: **** $p<0.0001$, 0.1g: ** $p=0.0027$. **I**, Inhibition of RVM neurons (CNO: 0.5 mg/kg, i.p.) increased the withdrawal latency in tail flick test; n=6 mice for each group; unpaired Student's t test. * $p=0.0298$, $t=2.531$, $df=10$. **J**, Mechanical itch test following saline or CNO injection in female WT mice pre-injected with AAV-hSyn-mCherry. n=5 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test. $F_{(1,56)}=0.2936$. 0.013g, 0.04g, 0.08g, 0.1g, 0.2g, 0.3g and 0.8g: $p > 0.9999$ for WT::mCherry+Saline vs. WT::mCherry+CNO. WT, wild-type. N.S., not significant.

Figure 2. Non-serotonergic but GABAergic GPER⁺ neurons were significantly activated in DCP-induced chronic contact dermatitis rat and mouse models.

A, Distinctive localization of GPER in RVM of female WT rat. Scale bar=200 μ m. **B**, High power image of boxed area in **A**. Scale bar=50 μ m. **C**, Percentage of GABAergic and non-GABAergic GPER⁺ neurons in the RVM of WT rats. 9 slides from 3 rats. **D**, **E**, Double IHC of GPER (green) and 5-HT (red) (**D**); GPER (green) and GAD67 (red) (**E**) in the RVM of female naïve rats. Scale bar=20 μ m. **F**, **G**, Double IHC showing the co-expression of GPER (green) and c-Fos (red) in the RVM of contact dermatitis female rat (**F**) and mouse (**G**) models. Scale bar=20 μ m.

Figure 3. Selective ablation of RVM GPER⁺ neurons aggravates acute and chronic itch.

A, Schematic showing the injection of AAV-DIO-taCasp3 into the RVM of female WT or Gper-Cre mice. **B**, **C**, Western blot showing the decreased expression of GPER protein in the RVM of Gper-Cre mice 35 days after AAV-DIO-taCasp3 injection. n=4 mice for each group; One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. $F=36.92$, *** $p = 0.0003$ for WT::taCasp3 vs. Gper-Cre::taCasp3, **** $p < 0.0001$ for WT vs. Gper-Cre::taCasp3. **D**, Apoptotic neurons in the RVM were examined using TUNEL staining. Scale bar=50 μ m. **E**, The number of apoptotic neurons in the RVM of female WT or Gper-Cre mice injected with AAV-CAG-DIO-taCasp3-TEVp. n=8-9 slides from 3 mice, unpaired Student's t test. **** $p < 0.0001$, $t=7.671$, $df=15$. **F**, Acute mechanical itch in GPER⁺ neuron-ablated Gper-Cre mice and control mice. n=10-11 mice for each group; Two- way

ANOVA followed by Bonferroni post hoc test. $F_{(1,133)}=26.65$, 0.08g: $*p=0.0299$, 0.3g: $*p=0.0316$. **G, H**, Ablation of RVM GPER⁺ neurons increased the scratching behavior in response to chloroquine (150 µg/20 µL) (**G**) and histamine (500 µg/20 µL) (**H**). n=8-10 mice for each group; unpaired Student's *t* test. $****p<0.0001$, $t=5.855$, df=14 for **G**; $*p=0.0215$, $t=2.548$, df=16 for **H**. **I**, Ablation of RVM GPER⁺ neurons increased the scratch bouts induced by DCP on every testing day. n=7-9 mice for each group. Difference in area under curve (AUC) was compared by unpaired Student's *t* test. $*p=0.0115$, $t=2.908$, df=14. **J, K**, Representative photograph of neck skin in DCP-treated female WT (**J**) and Gper-Cre (**K**) mice injected with AAV-DIO-taCasp3.

Figure 4. Chemogenetic inhibition or activation of RVM GPER⁺ neurons differentially modulates itch-related behaviors.

A, Schematic showing the injection of AAV-DIO-hM4Di-mCherry into the RVM of female Gper-Cre mice. **B**, Expression of hM4Di-mCherry in the RVM after viral infection. Scale bar = 50 µm. **C**, Acute mechanical itch test 30 min following saline or CNO injection (1 mg/kg, i.p.) in mice expressing hM4Di receptors in RVM GPER⁺ neurons. n=12 mice for each group; Two- way ANOVA followed by Bonferroni post hoc test. $F_{(1,154)}=99.52$, 0.013g: $****p<0.0001$, 0.04g: $***p=0.0001$, 0.08g: $****p<0.0001$, 0.1g: $*p=0.0356$, 0.3g: $**p=0.0100$. **D, E**, Effect of pharmacogenetic inhibition of GPER⁺ neurons in the RVM on scratching behavior induced by intradermal injection of chloroquine (150 µg/20 µL) (**D**) and histamine (500 µg/20 µL) (**E**). n=10-12 mice for each group; unpaired Student's *t* test. $**p=0.0028$, $t=3.382$, df=21 for **D**. $**p=0.0021$, $t=3.523$, df=20 for **E**. **F**, Time-dependent

changes in scratching bouts of DCP-treated Gper-Cre mice after viral infection, CNO were injected (i.p.) on day 5, 7 and 10 (gray frame), and the control group were injected with saline (i.p.). n=5 mice for each group. Note CNO-treated group had higher scratching bouts than the saline group on the days of treatment (day 5, 7 and 10), although statistical significance was not reached (a: $p=0.1022$, $t=0.1845$, $df=8$. b: $p=0.5456$, $t=0.6310$, $df=8$. c: $p=0.2258$, $t=1.312$, $df=8$). **G**, Schematic showing the injection of AAV-DIO-hM3Dq-eGFP into the RVM of female Gper-Cre mice. **H**, Expression of hM3Dq-eGFP in the RVM after viral infection. Scale bar, 50 μ m. **I**, Acute mechanical itch test following saline or CNO injection in mice expressing hM3Dq receptors in RVM GPER⁺ neurons. n=9 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test. $F_{(1,112)}=7.877$, 0.013g, 0.04g, 0.08g, 0.1g, 0.2g and 0.8g: $p>0.9999$; 0.3g: $p=0.4622$. **J**, **K**, Pharmacogenetic activation of RVM GPER⁺ neurons decreased scratching behavior induced by chloroquine (200 μ g/20 μ L) (**J**) and histamine (600 μ g/20 μ L) (**K**). n=6-9 mice for each group; CNO (1mg/kg, i.p.); unpaired Student's t test. $**p=0.0012$, $t=4.062$, $df=14$ for **J**. $***p=0.0005$, $t=4.916$, $df=11$ for **K**. **L**, Pharmacogenetic activation of RVM GPER⁺ neurons attenuated spontaneous scratching behavior on day 15 of contact dermatitis mouse models. n=4-5 mice for each group, unpaired Student's t test. $*p=0.0339$, $t=2.630$, $df=7$. N.S., not significant.

Figure 5. GPER deficiency results in hypersensitivity to itch in mice and rats.

A, Western blot showing that GPER protein expression in the RVM were increased in female contact dermatitis rat models. n=3 rats; unpaired Student's t test. $**p=0.0010$, $t=8.586$, $df=4$. **B**, Scratching bouts of WT and GPER^{-/-} rats in the normal physiological condition. n=5-6 rats

for each group. One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. $F=0.9604$. $p=0.9543$ for WT female vs. GPER^{-/-} female. $p=0.4076$ for WT male vs. GPER^{-/-} male. **C**, Acute mechanical itch test of female WT and GPER^{-/-} rats. $n=12-15$ rats; Two-way ANOVA followed by Bonferroni post hoc test. $F_{(1,225)}=66.01$, $0.2g$: $****p<0.0001$, $0.3g$: $**p=0.0029$, $0.6g$: $***p=0.0003$, $0.8g$: $*p=0.0136$. **D-F**, Scratching bouts of female WT and GPER^{-/-} rats induced by intradermal injection of chloroquine ($2.5\text{ mg}/50\text{ }\mu\text{L}$) (**D**), histamine ($2.5\text{ mg}/50\text{ }\mu\text{L}$) (**E**) and 5-HT ($200\text{ }\mu\text{g}/50\text{ }\mu\text{L}$) (**F**). $n=5-11$ rats; unpaired Student's t test. Chloroquine: $*p=0.0398$, $t=2.266$, $df=14$. Histamine: $*p=0.0302$, $t=2.487$, $df=11$. 5-HT: $**p=0.0081$, $t=2.938$, $df=20$. **G**, The number of scratching bouts of DCP-treated GPER^{-/-} rats were increased significantly on every testing day compared with WT rats. $n=6$ rats for each group. Difference in area under curve (AUC) was compared by unpaired Student's t test. $*p=0.0014$, $t=4.350$, $df=10$. **H**, GPER^{-/-} rats treated with DCP for 7 days showed increased spontaneous scratching behavior on the 8th day (without DCP treatment) compared to WT rats treated with DCP for 7 days. $n=16-18$ rats; unpaired Student's t test. $***p=0.0006$, $t=3.789$, $df=32$. **I**, Photograph of the back neck of a WT rat (shaved) before DCP treatment (left), DCP-treated WT rat on day 15 (middle) and DCP-treated GPER^{-/-} rat on day 15 (right). **J**, HE-stained skin before and after DCP treatment of WT and GPER^{-/-} rats. Scale bar=50 μm . **K**, The lesion severity score of neck skin in control rats, DCP-treated WT rats and GPER^{-/-} rats. 15 slides from 3 rats; One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. $F=53.14$, $****p<0.0001$ for WT vs. WT+DCP, WT+DCP vs. GPER^{-/-}+DCP and GPER^{-/-} vs. GPER^{-/-}+DCP.

Figure 6. GPER^{-/-} rats show increased scratching behavior than WT rats in imiquimod-induced psoriasis models.

A, The timeline for imiquimod-induced psoriasis-like rat model. **B, C**, Scratching behavior of female WT and GPER^{-/-} rats on each day before (**B**) and after (**C**) painting with imiquimod cream. n=5 rats for each group; area under curves (AUC) were compared by unpaired Student's *t* test. *t*=2.149, df=8 for **B**. *****p* < 0.0001, *t*=8.499, df=8 for **C**. **D**, Photograph of the back neck of imiquimod-treated WT and GPER^{-/-} rats on day 8. **E**, HE-stained neck skin of naïve and imiquimod-treatment female WT and GPER^{-/-} rats. Scale bar=50µm. **F**, The thickness of epidermis of neck skin in naïve and imiquimod-treated female WT rats and female GPER^{-/-} rats. 15 slides from 3 rats; One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. *F*=99.64, *****p* < 0.0001 for WT vs. WT IMQ and GPER^{-/-} vs. GPER^{-/-} IMQ. ****p*=0.0001 for WT IMQ vs. GPER^{-/-} IMQ. IMQ, imiquimod.

Figure 7. GPER-deficiency results in fewer activation of RVM neurons in contact dermatitis female rat models.

Representative IHC images and graph showing c-Fos⁺ neurons and serotonergic neurons in the RVM of naïve and DCP-treated WT and GPER^{-/-} rats. Scale bar=100 µm. The scatter plots show number of c-Fos⁺ neurons in 12 slides from 3 rats for naïve groups and 23-24 slides from 5 rats for DCP-treated groups. Differences were compared using one-way ANOVA and the Tukey post hoc tests. *F*=15.10, *****p* < 0.0001 for WT naïve vs. WT DCP, **p* = 0.0445 for WT DCP vs. GPER^{-/-} DCP, **p* = 0.0106 for GPER^{-/-} naïve vs. GPER^{-/-} DCP.

Figure 8. GPER^{-/-} mice are hypersensitive to chemical and mechanical itch.

A, Scratch bouts of female WT and GPER^{-/-} mice induced by intradermal injection of compound 48/80 (50 µg/20 µL). n=4-5 mice for each group; unpaired Student's *t* test. ****p*=0.0004, *t*=6.308, df=7. **B**, Systemic administration of G15 (0.5 mg/kg, i.p.) significantly increased scratching bouts of WT female mice induced by compound 48/80. n=4-5 mice; unpaired Student's *t* test. ****p*=0.0005, *t*=6.092, df=7. **C**, Acute mechanical itch test of WT and GPER^{-/-} female mice. n=8 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test. *F*_(1,154)=128.1, 0.013g: **p*=0.0232, 0.02g: ***p*=0.0019, 0.025g, 0.08g, 0.1g and 0.2g: *****p*<0.0001, 0.3g: **p*=0.0489. **D, E**, Scratching behavior of WT and GPER^{-/-} mice on each day before (**D**) and after (**E**) painting with imiquimod cream. n=4 mice for each group. Area under the curves (AUC) were compared using unpaired Student's *t* test. *p*=0.0613, *t*=2.298, df=6 for **D**. **p*=0.0287, *t*=2.863, df=6 for **E**. **F**, Photograph of the back neck and HE-stained skin of imiquimod-treated WT and GPER^{-/-} mice. Scale bar=50 µm. **G**, The lesion severity score of neck skin in imiquimod-treated WT and GPER^{-/-} mice. 4 slides from 4 mice; unpaired Student's *t* test. *p*=0.5847, *t*=0.5774, df=6. **H**, Acute mechanical itch test of WT and GPER^{-/-} male mice. n=8 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test. *F*_(1,154)=140.3, 0.013g, 0.02g and 0.025g: *****p*<0.0001, 0.04g: ****p*=0.0007, 0.08g: ****p*=0.0001, 0.1g: **p*=0.0185, 0.2g: ****p*=0.0007. **I, J**, Scratch bouts of male WT and GPER^{-/-} mice induced by intradermal injection of chloroquine (**I**, 150 µg/20 µL) and 5-HT (**J**, 10 µg/20 µL). n=6-8 mice for each group; unpaired Student's *t* test. *p*=0.1569, *t*=1.531, df=10 for **I**. *p*=0.1843, *t*=1.402, df=13 for **J**.

Figure 9. Male GPER^{-/-} rats are hypersensitive to mechanical and chemical itch.

A, Male GPER^{-/-} rats responded to light mechanical probing of the back neck by hind-paw scratching more vigorously than their WT counterparts. n=12 rats for each group. Two-way ANOVA followed by Bonferroni post hoc test. $F_{(1,198)}=110.6$, 0.2g, 0.6g, 0.8g and 2g: **** $p<0.0001$, 0.3g: *** $p=0.0003$, 4g: ** $p=0.0066$. **B**, Photograph of neck skin in DCP-treated male rats on day 8. **C**, HE-stained skin of naïve and DCP-treated male WT and GPER^{-/-} rats. Scale bar=100 μ m. **D**, Scratch bouts on every testing day of DCP-treated WT and GPER^{-/-} male rats. n=3-6 rats for each group; Area under the curves (AUC) were compared using unpaired Student's *t* test. ** $p=0.0070$, $t=3.773$, $df=7$. **E**, Spontaneous scratching behavior on day 8 of WT and GPER^{-/-} male rats. n=3-6 rats. unpaired Student's *t* test. * $p=0.0409$, $t=2.501$, $df=7$.

Figure 10. GPER modulates itch through regulating μ -opioid signaling.

A, Double IHC showing the co-expression of GPER (green) and MOR (red) in the RVM of WT rat. Scale bar, 50 μ m. **B**, Double staining of GPER and Leu enkephalin in RVM of female rat. Scale bar=10 μ m. **C-F**, Western blot showing increased MOR phosphorylation in the contact dermatitis female WT rats but not female GPER^{-/-} rats. n=3 rats for each group; One-way ANOVA and the Tukey post hoc test were used to assess statistical differences. p-MOR/MOR: $F=11.80$, ** $p=0.0026$ for WT vs. WT+DCP; P-MOR/ β -actin: $F=32.03$, *** $p=0.0004$ for WT vs. WT+DCP; MOR/ β -actin: $F=1.693$.

Figure 11. Hypersensitivity to itch in GPER^{-/-} rats or mice were reversed by the μ opioid

971 **antagonist naltrexone.**

972 **A, B,** Systemic administration of naltrexone (1 mg/kg, s.c.) resulted in reduction of
973 histamine-induced scratching (**A**) and scratching bouts under chronic itch conditions (**B**) of
974 female GPER^{-/-} rats. n=5 or 6; paired Student's *t* test. **p*=0.0435, *t*=2.914, df=4 for **A**;
975 **p*=0.0251, *t*=3.161, df=5 for **B**. **C, D,** Naltrexone (1 mg/kg, s.c.) reversed the
976 hyper-responsiveness to light mechanical stimulation in female (**C**) and male (**D**) GPER^{-/-}
977 mice. n=4 mice for each group; Two-way ANOVA followed by Bonferroni post hoc test.
978 *F*_(1,60)=28.12, 0.04g: **p*=0.0248, 0.08g: **p*=0.0498, 0.1g, **p*=0.0498 for **C**. *F*_(1,6)=48.98, 0.04g:
979 ****p*=0.0002, 0.08g: ***p*=0.0092, 0.1g, ****p*=0.0008, 0.2g, *****p*<0.0001, 0.3g, ***p*=0.0092
980 for **D**. s.c., subcutaneous. **E, F,** The mechanical itch response before and after the naltrexone
981 (1 mg/kg, s.c.) treatment in naïve WT male (**E**) and female (**F**) mice. n=5 mice for male group
982 and 6 mice for female group; Two-way ANOVA followed by Bonferroni post hoc test. **E**:
983 *F*_(1,72)=0.4081, 0.005g, 0.013g, 0.02g, 0.025g, 0.04g, 0.08g, 0.1g, 0.2g and 0.3g: *p*>0.9999. **F**:
984 *F*_(1,90)=1.366, 0.005g, 0.013g, 0.02g, 0.025g, 0.08g, 0.1g, 0.2g and 0.3g: *p*>0.9999, 0.04g:
985 *p*=0.1664. s.c., subcutaneous. N.S., not significant.

A **B** **C** **D** **E** **F** **G** **H** **I** **J**

A **B** **C** **D** **E**

A **B** **C** **D** **E** **F**

A **B** **C** **D** **E** **F**